Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628012 | 1.00 | NPSR1 (0.33) | NPSR1ALDH1A1TSHRPOLBFAAH | |
| SCHEMBL8228395 | 0.90 | CCR2 (0.33) | — | |
| SCHEMBL8240722 | 0.86 | NPSR1 (0.33) | NPSR1ALDH1A1POLBFAAHNAAA | |
| SCHEMBL10298837 | 0.83 | NPSR1 (0.32) | NPSR1ALDH1A1TSHRPOLBFAAH | |
| SCHEMBL2435478 | 0.82 | GAA (0.32) | TSHRFAAHNAAAHSD17B10 | |
| SCHEMBL2435477 | 0.80 | MAPK1 (0.35) | NPSR1HSD17B10 | |
| SCHEMBL2756144 | 0.78 | — | — | |
| SCHEMBL22122404 | 0.76 | RAB9A (0.41) | NPSR1ALDH1A1TSHRPOLBFAAH | |
| SCHEMBL2059432 | 0.76 | RAB9A (0.41) | NPSR1ALDH1A1TSHRPOLBFAAH | |
| SCHEMBL9972392 | 0.76 | SMN1; SMN2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | NPSR1 4296/4885ALDH1A1 2858/4885TSHR 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.